

- **Name:** **Jihoon Kang**
  - **Current Position & Affiliation:** **Clinical Assistant Professor, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine**
  - **Country:** **Korea**
- 

• **Educational Background:**

- 2002. 3 – 2008. 2 M.D.  
Medical College of Chungnam National University
- 2011. 3 – 2013.2 Master of Science in Medicine  
Postgraduate School, University of Ulsan College of Medicine

• **Professional Experience:**

- 2008. 3 – 2009.2 Internship  
Asan Medical Center,  
University of Ulsan College of Medicine  
Seoul, Korea
- 2009. 3 – 2013.2 Residency, Internal Medicine,  
Asan Medical Center,  
University of Ulsan College of Medicine  
Seoul, Korea
- 2016. 3 – 2018.2 Clinical fellowship  
Department of Oncology, Asan Medical Center,  
University of Ulsan College of Medicine, Seoul, Korea
- 2018.3 – Clinical Assistant Professor  
Division of Hematology/Oncology, Kangbuk Samsung Hospital  
Sungkyunkwan University School of Medicine, Seoul, Korea

• **Professional Organizations:**

- Member, American Society of Clinical Oncology
- Member, European Society of Medical Oncology
- Member, Korean Society of Medical Oncology
- Member, Korean Cancer Study Group

**• Main Scientific Publications:**

1. Jihoon Kang, Yoosoo Chang, Jiin Ahn, Sukjoong Oh, Dong-Hoe Koo, Yun-Gyoo Lee, Hocheol Shin, Seungho Ryu: Neutrophil-to-lymphocyte ratio and risk of lung cancer mortality in a low-risk population: A cohort study: *Int J Cancer* 2019;145(12):3267-3275
2. Changhoon Yoo\*, Jihoon Kang\*, Ho Yeong Lim, Jee Hyun Kim, Myung-Ah Lee, Kyung-Hun Lee, Tae-You Kim, Baek-Yeol Ryoo: Phase I dose finding study of OPB-111077, a Novel STAT3 Inhibitor, in patients with Advanced Hepatocellular carcinoma: *Cancer Res Treat* 2019;51(2):510-518 \*1st coauthor
3. Jihoon Kang, Jung Yong Hong, Dok Hyun Yoon, Jeong Eun Kim, Kyu-pyo Kim, Shin Kim, Kyoung Min Lee, Jung Sun Park, Ji Sung Lee, and Cheolwon Suh: Pharmacokinetic and pharmacodynamic study of lenograstim for hematopoietic stem cell mobilization: a prospective randomized study for optimal apheresis: *Transfusion* 2019;59(5):1781-1788
4. Inhwang Hwang\*, Jihoon Kang\*, Hei Nga Natalie Ip, Jae Ho Jeong, Kyu-pyo Kim, Heung-Moon Chang, Changhoon Yoo, Baek-Yeol Ryoo: Prognostic factors in patients with metastatic or recurrent pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine: implication of inflammation-based scores: *Invest New Drugs* 2019;37(3):584-590 \*1st coauthor
5. Jihoon Kang\*, Inhwang Hwang\*, Changhoon Yoo, Kyu-pyo Kim, Jae Ho Jeong, Heung-Moon Chang, Sang Soo Lee, Do Hyun Park, Tae Jun Song, Dong Wan Seo, Sung Koo Lee, Myung-Hwan Kim, Seung-Mo Hong, Sang Hyun Shin, Dae Wook Hwang, Ki Byung Song, Jae Hoon Lee, Song Cheol Kim, Baek-Yeol Ryoo: Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis: *Invest New Drugs* 2018;36(4):732-741 \*1st coauthor
6. Jihoon Kang, Jung Yong Hong, Dok Hyun Yoon, Shin Kim, Kyoung Min Lee, Jung Sun Park, Chan-Jeoung Park, Won-Ki Min, Eul-Ju Seo, Seongsoo Jang, Cheolwon Suh: Efficacy and survival outcome associated with the use of novel agents and autologous stem cell transplantation in cases of immunoglobulin D multiple myeloma in Korea: *Acta Haematologica* 2018;139(3):185-192
7. Jihoon Kang, Jung Yong Hong, Cheolwon Suh: Clinical features and survival outcomes for patients with lymphoplasmacytic lymphoma, including non-IgM type, in Korea: a single center experience: *Blood Res* 2018;53:189-197